## **Guy Boivin**

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8630293/publications.pdf

Version: 2024-02-01

15495 25770 14,571 261 65 108 citations h-index g-index papers 271 271 271 12165 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Virological Features and Clinical Manifestations Associated with Human Metapneumovirus: A New Paramyxovirus Responsible for Acute Respiratoryâ€Tract Infections in All Age Groups. Journal of Infectious Diseases, 2002, 186, 1330-1334.	1.9	527
2	Resistance of Herpes Simplex Viruses to Nucleoside Analogues: Mechanisms, Prevalence, and Management. Antimicrobial Agents and Chemotherapy, 2011, 55, 459-472.	1.4	428
3	Human Metapneumovirus Infections in Hospitalized Children 1. Emerging Infectious Diseases, 2003, 9, 634-640.	2.0	395
4	Quantitation of Cytomegalovirus: Methodologic Aspects and Clinical Applications. Clinical Microbiology Reviews, 1998, 11, 533-554.	5.7	376
5	Characterization of Human Metapneumoviruses Isolated from Patients in North America. Journal of Infectious Diseases, 2002, 185, 1660-1663.	1.9	362
6	Pandemics Throughout History. Frontiers in Microbiology, 2020, 11, 631736.	1.5	330
7	Influenza virus resistance to neuraminidase inhibitors. Antiviral Research, 2013, 98, 174-185.	1.9	300
8	Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resistance Updates, 2002, 5, 88-114.	6.5	277
9	Association between the 2008–09 Seasonal Influenza Vaccine and Pandemic H1N1 Illness during Spring–Summer 2009: Four Observational Studies from Canada. PLoS Medicine, 2010, 7, e1000258.	3.9	266
10	Genetic diversity between human metapneumovirus subgroups. Virology, 2003, 315, 1-9.	1.1	219
11	Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respiratory Medicine,the, 2021, 9, 924-932.	<b>5.</b> 2	218
12	Respiratory Tract Reinfections by the New Human Metapneumovirus in an Immunocompromised Child. Emerging Infectious Diseases, 2002, 8, 976-978.	2.0	207
13	Emergence of Oseltamivir-Resistant Pandemic H1N1 Virus during Prophylaxis. New England Journal of Medicine, 2009, 361, 2296-2297.	13.9	204
14	Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Research, 2003, 60, 51-59.	1.9	186
15	An Outbreak of Severe Respiratory Tract Infection Due to Human Metapneumovirus in a Long-Term Care Facility. Clinical Infectious Diseases, 2007, 44, 1152-1158.	2.9	183
16	Characterization of Multidrug-Resistant Influenza A/H3N2 Viruses Shed during 1 Year by an Immunocompromised Child. Clinical Infectious Diseases, 2006, 43, 1555-1561.	2.9	174
17	Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine, 2008, 26, 3395-3403.	1.7	172
18	Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infectious Diseases, 2011, 11, 134.	1.3	171

#	Article	IF	Citations
19	Generation and Characterization of Recombinant Influenza A (H1N1) Viruses Harboring Amantadine Resistance Mutations. Antimicrobial Agents and Chemotherapy, 2005, 49, 556-559.	1.4	169
20	Human Metapneumovirus: A New Player among Respiratory Viruses. Clinical Infectious Diseases, 2004, 38, 983-990.	2.9	167
21	Absence of Cytomegalovirusâ€Resistance Mutations after Valganciclovir Prophylaxis, in a Prospective Multicenter Study of Solidâ€Organ Transplant Recipients. Journal of Infectious Diseases, 2004, 189, 1615-1618.	1.9	158
22	Impact of Neuraminidase Mutations Conferring Influenza Resistance to Neuraminidase Inhibitors in the N1 and N2 Genetic Backgrounds. Antiviral Therapy, 2006, 11, 971-976.	0.6	155
23	Influenza Virus Susceptibility and Resistance to Oseltamivir. Antiviral Therapy, 2007, 12, 603-616.	0.6	152
24	Antiviral Susceptibilities and Analysis of UL97 and DNA Polymerase Sequences of Clinical Cytomegalovirus Isolates from Immunocompromised Patients. Journal of Infectious Diseases, 1997, 175, 1087-1092.	1.9	148
25	Generation and Characterization of Recombinant Pandemic Influenza A(H1N1) Viruses Resistant to Neuraminidase Inhibitors. Journal of Infectious Diseases, 2011, 203, 25-31.	1.9	136
26	Tumor Necrosis Factor–α and Interleukinâ€1β Play a Critical Role in the Resistance against Lethal Herpes Simplex Virus Encephalitis. Journal of Infectious Diseases, 2007, 196, 853-860.	1.9	135
27	The Importance of Frailty in the Assessment of Influenza Vaccine Effectiveness Against Influenza-Related Hospitalization in Elderly People. Journal of Infectious Diseases, 2017, 216, 405-414.	1.9	133
28	Modified cyclodextrins as broad-spectrum antivirals. Science Advances, 2020, 6, eaax9318.	4.7	131
29	Rate of Emergence of Cytomegalovirus (CMV) Mutations in Leukocytes of Patients with Acquired Immunodeficiency Syndrome Who Are Receiving Valganciclovir as Induction and Maintenance Therapy for CMV Retinitis. Journal of Infectious Diseases, 2001, 184, 1598-1602.	1.9	124
30	Global Genetic Diversity of Human Metapneumovirus Fusion Gene. Emerging Infectious Diseases, 2004, 10, 1154-1157.	2.0	122
31	Comparison of Risk Factors for Human Metapneumovirus and Respiratory Syncytial Virus Disease Severity in Young Children. Journal of Infectious Diseases, 2012, 206, 178-189.	1.9	122
32	Comparative Evaluation of Real-Time PCR Assays for Detection of the Human Metapneumovirus. Journal of Clinical Microbiology, 2003, 41, 3631-3635.	1.8	117
33	Effect of the Neuraminidase Mutation H274Y Conferring Resistance to Oseltamivir on the Replicative Capacity and Virulence of Old and Recent Human Influenza A(H1N1) Viruses. Journal of Infectious Diseases, 2010, 201, 740-745.	1.9	116
34	Antiviral drug resistance in herpesviruses other than cytomegalovirus. Reviews in Medical Virology, 2014, 24, 186-218.	3.9	115
35	Sequence analysis of the N, P, M and F genes of Canadian human metapneumovirus strains. Virus Research, 2003, 93, 51-62.	1.1	112
36	Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: diagnosis and management. Current Opinion in Infectious Diseases, 2016, 29, 654-662.	1.3	112

#	Article	IF	Citations
37	Viral Interference between Respiratory Viruses. Emerging Infectious Diseases, 2022, 28, 273-281.	2.0	108
38	Optimization of Droplet Digital PCR from RNA and DNA extracts with direct comparison to RT-qPCR: Clinical implications for quantification of Oseltamivir-resistant subpopulations. Journal of Virological Methods, 2015, 224, 58-66.	1.0	107
39	Effect of Ribavirin and Glucocorticoid Treatment in a Mouse Model of Human Metapneumovirus Infection. Antimicrobial Agents and Chemotherapy, 2006, 50, 774-777.	1.4	106
40	Household Transmission of the 2009 Pandemic A/H1N1 Influenza Virus: Elevated Laboratoryâ€Confirmed Secondary Attack Rates and Evidence of Asymptomatic Infections. Clinical Infectious Diseases, 2010, 51, 1033-1041.	2.9	102
41	Pathogenesis of Human Metapneumovirus Lung Infection in BALB/c Mice and Cotton Rats. Journal of Virology, 2005, 79, 8894-8903.	1.5	99
42	The H275Y Neuraminidase Mutation of the Pandemic A/H1N1 Influenza Virus Lengthens the Eclipse Phase and Reduces Viral Output of Infected Cells, Potentially Compromising Fitness in Ferrets. Journal of Virology, 2012, 86, 10651-10660.	1.5	99
43	Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations. Journal of Clinical Virology, 2009, 46, 129-133.	1.6	94
44	Characterization of the DNA Polymerase and Thymidine Kinase Genesof Herpes Simplex Virus Isolates from AIDS Patients in whom Acyclovirand Foscarnet Therapy Sequentially Failed. Journal of Infectious Diseases, 1999, 180, 487-490.	1.9	92
45	Risk factors for hospitalization and severe outcomes of 2009 pandemic H1N1 influenza in Quebec, Canada. Influenza and Other Respiratory Viruses, 2011, 5, 247-255.	1.5	91
46	DNA vaccination protects mice against Zika virus-induced damage to the testes. Nature Communications, 2017, 8, 15743.	5.8	90
47	A Trial of Valganciclovir Prophylaxis for Cytomegalovirus Prevention in Lung Transplant Recipients. American Journal of Transplantation, 2005, 5, 1462-1468.	2.6	89
48	Comparison of Automated Microarray Detection with Real-Time PCR Assays for Detection of Respiratory Viruses in Specimens Obtained from Children. Journal of Clinical Microbiology, 2009, 47, 743-750.	1.8	88
49	Distribution and Clinical Impact of Human Respiratory Syncytial Virus Genotypes in Hospitalized Children over 2 Winter Seasons. Journal of Infectious Diseases, 2006, 193, 54-58.	1.9	87
50	Human Metapneumovirus Infection Induces Longâ€Term Pulmonary Inflammation Associated with Airway Obstruction and Hyperresponsiveness in Mice. Journal of Infectious Diseases, 2006, 193, 1634-1642.	1.9	87
51	Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antiviral Therapy, 2009, 14, 697-704.	0.6	86
52	Oseltamivir-Resistant Pandemic A/H1N1 Virus Is as Virulent as Its Wild-Type Counterpart in Mice and Ferrets. PLoS Pathogens, 2010, 6, e1001015.	2.1	85
53	A collaborative study to establish the 1st WHO International Standard for human cytomegalovirus for nucleic acid amplification technology. Biologicals, 2016, 44, 242-251.	0.5	85
54	Drug Resistance Patterns of Recombinant Herpes Simplex Virus DNA Polymerase Mutants Generated with a Set of Overlapping Cosmids and Plasmids. Journal of Virology, 2003, 77, 7820-7829.	1.5	82

#	Article	IF	CITATIONS
55	Cross-reactive and Vaccine-Induced Antibody to an Emerging Swine-Origin Variant of Influenza A Virus Subtype H3N2 (H3N2v). Journal of Infectious Diseases, 2012, 206, 1852-1861.	1.9	82
56	Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antiviral Therapy, 2006, 11, 971-6.	0.6	81
57	A Reverse Genetics Study of Resistance to Neuraminidase Inhibitors in An Influenza A/H1N1 Virus. Antiviral Therapy, 2004, 9, 577-581.	0.6	75
58	Influenza virus susceptibility and resistance to oseltamivir. Antiviral Therapy, 2007, 12, 603-16.	0.6	74
59	Rapid Antiviral Effect of Inhaled Zanamivir in the Treatment of Naturally Occurring Influenza in Otherwise Healthy Adults. Journal of Infectious Diseases, 2000, 181, 1471-1474.	1.9	73
60	Prolonged Excretion of Amantadine-Resistant Influenza A Virus Quasi Species after Cessation of Antiviral Therapy in an Immunocompromised Patient. Clinical Infectious Diseases, 2002, 34, e23-e25.	2.9	73
61	The distinguishing features of human metapneumovirus and respiratory syncytial virus. Reviews in Medical Virology, 2010, 20, 245-260.	3.9	73
62	Infection with Human Metapneumovirus Predisposes Mice to Severe Pneumococcal Pneumonia. Journal of Virology, 2009, 83, 1341-1349.	1.5	72
63	Role of Permissive Neuraminidase Mutations in Influenza A/Brisbane/59/2007-like (H1N1) Viruses. PLoS Pathogens, 2011, 7, e1002431.	2.1	71
64	Presence of Oseltamivir-Resistant Pandemic A/H1N1 Minor Variants Before Drug Therapy With Subsequent Selection and Transmission. Journal of Infectious Diseases, 2012, 206, 1504-1511.	1.9	70
65	Delayed but Not Early Glucocorticoid Treatment Protects the Host during Experimental Herpes Simplex Virus Encephalitis in Mice. Journal of Infectious Diseases, 2007, 195, 817-825.	1.9	69
66	Influenza Drug Resistance. Seminars in Respiratory and Critical Care Medicine, 2011, 32, 409-422.	0.8	69
67	Herpesvirus DNA polymerases: Structures, functions and inhibitors. Virus Research, 2017, 234, 177-192.	1.1	68
68	Effectiveness of Influenza Vaccination on Hospitalizations and Risk Factors for Severe Outcomes in Hospitalized Patients With COPD. Chest, 2019, 155, 69-78.	0.4	67
69	Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance. Antiviral Research, 2019, 163, 91-105.	1.9	66
70	Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. Antiviral Research, 2002, 54, 143-147.	1.9	64
71	Treatment of respiratory virus infections. Antiviral Research, 2006, 70, 1-16.	1.9	64
72	Sequence polymorphism of the predicted human metapneumovirus G glycoprotein. Journal of General Virology, 2004, 85, 679-686.	1.3	62

#	Article	IF	CITATIONS
73	Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir. Antiviral Research, 2007, 74, 159-162.	1.9	61
74	Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. Journal of Medical Virology, 2005, 77, 425-429.	2.5	60
75	Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes. Antiviral Research, 2008, 77, 163-166.	1.9	59
76	Effect of Pretreatment with Tollâ€like Receptor Agonists in a Mouse Model of Herpes Simplex Virus Type 1 Encephalitis. Journal of Infectious Diseases, 2008, 198, 664-672.	1.9	59
77	Intrahost Dynamics of Antiviral Resistance in Influenza A Virus Reflect Complex Patterns of Segment Linkage, Reassortment, and Natural Selection. MBio, 2015, 6, .	1.8	58
78	Characterization of 2 Influenza A(H3N2) Clinical Isolates with Reduced Susceptibility to Neuraminidase Inhibitors Due to Mutations in the Hemagglutinin Gene. Journal of Infectious Diseases, 2002, 186, 1074-1080.	1.9	57
79	Highly Reliable Heterologous System for Evaluating Resistance of Clinical Herpes Simplex Virus Isolates to Nucleoside Analogues. Journal of Virology, 2001, 75, 3105-3110.	1.5	56
80	Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories. Vaccine Journal, 2016, 23, 236-242.	3.2	55
81	Assessing the In Vitro Fitness of an Oseltamivir-Resistant Seasonal A/H1N1 Influenza Strain Using a Mathematical Model. PLoS ONE, 2011, 6, e14767.	1.1	54
82	E119D Neuraminidase Mutation Conferring Pan-Resistance to Neuraminidase Inhibitors in an A(H1N1)pdm09 Isolate From a Stem-Cell Transplant Recipient. Journal of Infectious Diseases, 2015, 212, 1726-1734.	1.9	54
83	Human metapneumovirus: Enhanced pulmonary disease in cotton rats immunized with formalin-inactivated virus vaccine and challenged. Vaccine, 2007, 25, 5034-5040.	1.7	53
84	Impact of Mutations at Residue I223 of the Neuraminidase Protein on the Resistance Profile, Replication Level, and Virulence of the 2009 Pandemic Influenza Virus. Antimicrobial Agents and Chemotherapy, 2012, 56, 1208-1214.	1.4	53
85	Structural Insight into NS5 of Zika Virus Leading to the Discovery of MTase Inhibitors. Journal of the American Chemical Society, 2016, 138, 16212-16215.	6.6	52
86	Influenza vaccine effectiveness to prevent influenza-related hospitalizations and serious outcomes in Canadian adults over the 2011/12 through 2013/14 influenza seasons: A pooled analysis from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS Network). Vaccine, 2018, 36, 2166-2175.	1.7	52
87	Identification and Evaluation of a Highly Effective Fusion Inhibitor for Human Metapneumovirus. Antimicrobial Agents and Chemotherapy, 2008, 52, 279-287.	1.4	51
88	Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains. Journal of Infectious Diseases, 2020, 221, 63-70.	1.9	51
89	Detection and management of antiviral resistance for influenza viruses. Influenza and Other Respiratory Viruses, 2013, 7, 18-23.	1.5	50
90	Antiviral Agents in Development for Zika Virus Infections. Pharmaceuticals, 2019, 12, 101.	1.7	50

#	Article	IF	Citations
91	Enhanced lung disease and Th2 response following human metapneumovirus infection in mice immunized with the inactivated virus. Journal of General Virology, 2007, 88, 3391-3400.	1.3	48
92	Intranasal herpes simplex virus type 2 inoculation causes a profound thymidine kinase dependent cerebral inflammatory response in the mouse hindbrain. European Journal of Neuroscience, 2002, 16, 29-43.	1.2	46
93	Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis. Journal of Clinical Virology, 2012, 53, 208-213.	1.6	46
94	Impact of the H275Y and I223V Mutations in the Neuraminidase of the 2009 Pandemic Influenza Virus In Vitro and Evaluating Experimental Reproducibility. PLoS ONE, 2015, 10, e0126115.	1.1	46
95	Emergence and prevalence of cytomegalovirus UL97 mutations associated with ganciclovir resistance in AIDS patients. Aids, 1998, 12, 125-129.	1.0	45
96	Impact of Potential Permissive Neuraminidase Mutations on Viral Fitness of the H275Y Oseltamivir-Resistant Influenza A(H1N1)pdm09 Virus <i>In Vitro </i> , in Mice and in Ferrets. Journal of Virology, 2014, 88, 1652-1658.	1.5	44
97	Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures. Frontiers in Immunology, 2019, 10, 60.	2.2	44
98	Effects of Different Adjuvants in the Context of Intramuscular and Intranasal Routes on Humoral and Cellular Immune Responses Induced by Detergent-Split A/H3N2 Influenza Vaccines in Mice. Vaccine Journal, 2012, 19, 209-218.	3.2	42
99	Immunomodulatory Strategies in Herpes Simplex Virus Encephalitis. Clinical Microbiology Reviews, 2020, 33, .	5.7	42
100	Genetic diversity and molecular evolution of the major human metapneumovirus surface glycoproteins over a decade. Journal of Clinical Virology, 2013, 58, 541-547.	1.6	41
101	Virus-like particle vaccine induces cross-protection against human metapneumovirus infections in mice. Vaccine, 2013, 31, 2778-2785.	1.7	41
102	Characterization of Drug-Resistant Influenza Virus A(H1N1) and A(H3N2) Variants Selected <i>In Vitro </i> Vitro Vitro Vitro	1.4	41
103	Quantification of human herpesvirus 8 by real-time PCR in blood fractions of AIDS patients with Kaposi's sarcoma and multicentric Castleman's disease. Journal of Medical Virology, 2002, 68, 399-403.	2.5	40
104	Cross-Lineage Influenza B and Heterologous Influenza A Antibody Responses in Vaccinated Mice: Immunologic Interactions and B/Yamagata Dominance. PLoS ONE, 2012, 7, e38929.	1.1	40
105	Cytomegalovirus Seropositivity Is Associated With Increased Microbial Translocation in People Living With Human Immunodeficiency Virus and Uninfected Controls. Clinical Infectious Diseases, 2020, 71, 1438-1446.	2.9	40
106	Divergent evolution of hemagglutinin and neuraminidase genes in recent influenza A:H3N2 viruses isolated in Canada. Journal of Medical Virology, 2002, 67, 589-595.	2.5	39
107	The I222V Neuraminidase Mutation Has a Compensatory Role in Replication of an Oseltamivir-Resistant Influenza Virus A/H3N2 E119V Mutant. Journal of Clinical Microbiology, 2011, 49, 715-717.	1.8	38
108	The 2009 Pandemic H1N1 D222G Hemagglutinin Mutation Alters Receptor Specificity and Increases Virulence in Mice but Not in Ferrets. Journal of Infectious Diseases, 2011, 204, 1008-1016.	1.9	38

#	Article	IF	Citations
109	Valacyclovir combined with artesunate or rapamycin improves the outcome of herpes simplex virus encephalitis in mice compared to antiviral therapy alone. Antiviral Research, 2015, 123, 105-113.	1.9	38
110	Evaluation of Susceptibility of Human Herpesvirus 8 to Antiviral Drugs by Quantitative Real-Time PCR. Journal of Clinical Microbiology, 2003, 41, 3897-3900.	1.8	37
111	Human respiratory syncytial virus and other viral infections in infants receiving palivizumab. Journal of Clinical Virology, 2008, 42, 52-57.	1.6	37
112	A Novel Neuraminidase Deletion Mutation Conferring Resistance to Oseltamivir in Clinical Influenza A/H3N2 Virus. Journal of Infectious Diseases, 2009, 199, 180-183.	1.9	37
113	Antibody persistence and response to 2010–2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children. Vaccine, 2011, 30, 35-41.	1.7	36
114	Artesunate Demonstrates <i>in vitro</i> Synergism with Several Antiviral Agents against Human Cytomegalovirus. Antiviral Therapy, 2016, 21, 535-539.	0.6	36
115	A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir. Open Forum Infectious Diseases, 2017, 4, ofx105.	0.4	36
116	Innate immune response during herpes simplex virus encephalitis and development of immunomodulatory strategies. Reviews in Medical Virology, 2015, 25, 300-319.	3.9	35
117	Targeted Proteomics of Human Metapneumovirus in Clinical Samples and Viral Cultures. Analytical Chemistry, 2015, 87, 10247-10254.	3.2	35
118	A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus. Antiviral Therapy, 2004, 9, 577-81.	0.6	35
119	Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis. Journal of Clinical Virology, 2010, 47, 321-324.	1.6	34
120	Frailty Hinders Recovery From Influenza and Acute Respiratory Illness in Older Adults. Journal of Infectious Diseases, 2020, 222, 428-437.	1.9	34
121	Prophylactic and therapeutic benefits of a monoclonal antibody against the fusion protein of human metapneumovirus in a mouse model. Antiviral Research, 2010, 88, 31-37.	1.9	33
122	Modulation of Protease Activated Receptor 1 Influences Human Metapneumovirus Disease Severity in a Mouse Model. PLoS ONE, 2013, 8, e72529.	1.1	33
123	Characterization of cellular transcriptomic signatures induced by different respiratory viruses in human reconstituted airway epithelia. Scientific Reports, 2019, 9, 11493.	1.6	33
124	Molecular Evolution of Respiratory Syncytial Virus Fusion Gene, Canada, 2006–2010. Emerging Infectious Diseases, 2012, 18, 120-124.	2.0	31
125	Design considerations in building <i>in silico </i> equivalents of common experimental influenza virus assays. Autoimmunity, 2011, 44, 282-293.	1.2	30
126	Both TRIF and IPS-1 Adaptor Proteins Contribute to the Cerebral Innate Immune Response against Herpes Simplex Virus 1 Infection. Journal of Virology, 2013, 87, 7301-7308.	1.5	30

#	Article	IF	CITATIONS
127	Novel Method Based on "En Passant―Mutagenesis Coupled with a Gaussia Luciferase Reporter Assay for Studying the Combined Effects of Human Cytomegalovirus Mutations. Journal of Clinical Microbiology, 2013, 51, 3216-3224.	1.8	30
128	Cell Culture Systems To Study Human Herpesvirus 6A/B Chromosomal Integration. Journal of Virology, 2017, 91, .	1.5	30
129	Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN). Vaccine, 2019, 37, 5466-5473.	1.7	29
130	Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy. Journal of Medical Virology, 2002, 67, 88-91.	2.5	28
131	Role of Helix P of the Human Cytomegalovirus DNA Polymerase in Resistance and Hypersusceptibility to the Antiviral Drug Foscarnet. Journal of Virology, 2006, 80, 1440-1450.	1.5	28
132	Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet. Antimicrobial Agents and Chemotherapy, 2011, 55, 4019-4027.	1.4	28
133	Human metapneumovirus viral load is an important risk factor for disease severity in young children. Journal of Clinical Virology, 2014, 60, 133-140.	1.6	28
134	Infiltration Pattern of Blood Monocytes into the Central Nervous System during Experimental Herpes Simplex Virus Encephalitis. PLoS ONE, 2015, 10, e0145773.	1.1	28
135	Resource utilization and cost of influenza requiring hospitalization in Canadian adults: A study from the serious outcomes surveillance network of the Canadian Immunization Research Network. Influenza and Other Respiratory Viruses, 2018, 12, 232-240.	1.5	28
136	Characterization of Multiple Cytomegalovirus Drug Resistance Mutations Detected in a Hematopoietic Stem Cell Transplant Recipient by Recombinant Phenotyping. Journal of Clinical Microbiology, 2014, 52, 4043-4046.	1.8	26
137	Phenotypic Evaluation of Previously Uncharacterized Cytomegalovirus DNA Polymerase Sequence Variants Detected in a Valganciclovir Treatment Trial. Journal of Infectious Diseases, 2014, 209, 1219-1226.	1.9	26
138	Evolution of Oseltamivir Resistance Mutations in Influenza A(H1N1) and A(H3N2) Viruses during Selection in Experimentally Infected Mice. Antimicrobial Agents and Chemotherapy, 2014, 58, 6398-6405.	1.4	26
139	Novel Method Based on Real-Time Cell Analysis for Drug Susceptibility Testing of Herpes Simplex Virus and Human Cytomegalovirus. Journal of Clinical Microbiology, 2016, 54, 2120-2127.	1.8	26
140	Burden of vaccine-preventable pneumococcal disease in hospitalized adults: A Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) network study. Vaccine, 2017, 35, 3647-3654.	1.7	26
141	Influenza A(H1N1)pdm09 Virus but Not Respiratory Syncytial Virus Interferes with SARS-CoV-2 Replication during Sequential Infections in Human Nasal Epithelial Cells. Viruses, 2022, 14, 395.	1.5	26
142	Characterization of Human Cytomegalovirus (HCMV) UL97 Mutations Found in a Valganciclovir/Oral Ganciclovir Prophylactic Trial by Use of a Bacterial Artificial Chromosome Containing the HCMV Genome. Journal of Infectious Diseases, 2006, 194, 579-583.	1.9	25
143	Viral Pathogens Including Human Metapneumovirus Are the Primary Cause of Febrile Respiratory Illness in HIVâ€Infected Adults Receiving Antiretroviral Therapy. Journal of Infectious Diseases, 2010, 201, 297-301.	1.9	25
144	OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes. Npj Vaccines, 2019, 4, 4.	2.9	25

#	Article	IF	Citations
145	The Prophylactic Administration of a Monoclonal Antibody against Human Metapneumovirus Attenuates viral Disease and Airways Hyperresponsiveness in Mice. Antiviral Therapy, 2008, 13, 39-46.	0.6	25
146	Impact of deficiency in CCR2 and CX3CR1 receptors on monocytes trafficking in herpes simplex virus encephalitis. Journal of General Virology, 2012, 93, 1294-1304.	1.3	24
147	Modulation of TLR9 response in a mouse model of herpes simplex virus encephalitis. Antiviral Research, 2012, 96, 414-421.	1.9	24
148	Molecular and antigenic evolution of human influenza A/H3N2 viruses in Quebec, Canada, 2009–2011. Journal of Clinical Virology, 2012, 53, 88-92.	1.6	24
149	Host and Viral Factors Affecting Clinical Performance of a Rapid Diagnostic Test for Respiratory Syncytial Virus in Hospitalized Children. Journal of Pediatrics, 2013, 163, 911-913.	0.9	24
150	Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus. Viruses, 2018, 10, 610.	1.5	24
151	Recent developments with liveâ€attenuated recombinant paramyxovirus vaccines. Reviews in Medical Virology, 2013, 23, 15-34.	3.9	23
152	Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antiviral Therapy, 2009, 14, 697-704.	0.6	23
153	A case of ganciclovir-resistant cytomegalovirus (CMV) retinitis in a patient with AIDS. Aids, 1997, 11, 867-873.	1.0	22
154	Thymidine Kinase Mutations Conferring Acyclovir Resistance in Herpes Simplex Type 1 Recombinant Viruses. Antimicrobial Agents and Chemotherapy, 2006, 50, 3889-3892.	1.4	22
155	Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis. Transplantation, 2010, 90, 1409-1413.	0.5	22
156	Longitudinal evaluation of herpes simplex virus DNA load during episodes of herpes labialis. Journal of Clinical Virology, 2006, 37, 248-251.	1.6	21
157	Influenza vaccine effectiveness against influenza-related hospitalization during a season with mixed outbreaks of four influenza viruses: a test-negative case-control study in adults in Canada. BMC Infectious Diseases, 2017, 17, 805.	1.3	21
158	The Nonstructural NS1 Protein of Influenza Viruses Modulates <i>TP53</i> Splicing through Host Factor CPSF4. Journal of Virology, 2019, 93, .	1.5	21
159	An Early Microglial Response Is Needed To Efficiently Control Herpes Simplex Virus Encephalitis. Journal of Virology, 2020, 94, .	1.5	21
160	Age-stratified burden of pneumococcal community acquired pneumonia in hospitalised Canadian adults from 2010 to 2015. BMJ Open Respiratory Research, 2020, 7, e000550.	1.2	21
161	Inhibition of Human Metapneumovirus Replication by Small Interfering RNA. Antiviral Therapy, 2008, 13, 821-832.	0.6	21
162	Three-dimensional modeling of cytomegalovirus DNA polymerase and preliminary analysis of drug resistance. Proteins: Structure, Function and Bioinformatics, 2006, 64, 301-307.	1.5	20

#	Article	IF	Citations
163	RSV and HMPV Infections in 3D Tissue Cultures: Mechanisms Involved in Virus-Host and Virus-Virus Interactions. Viruses, 2021, 13, 139.	1.5	20
164	Role of Picornaviruses in Flu-Like Illnesses of Adults Enrolled in an Oseltamivir Treatment Study Who Had No Evidence of Influenza Virus Infection. Journal of Clinical Microbiology, 2002, 40, 330-334.	1.8	19
165	Discordant phenotypes and genotypes of Cytomegalovirus (CMV) in patients with AIDS and relapsing CMV retinitis. Aids, 2003, 17, 337-341.	1.0	19
166	Prophylactic Activity of Intramuscular Peramivir in Mice Infected with a Recombinant Influenza A/WSN/33 (H1N1) Virus Containing the H274Y Neuraminidase Mutation. Antimicrobial Agents and Chemotherapy, 2010, 54, 2819-2822.	1.4	19
167	Evaluation of Serological Diagnostic Methods for the 2009 Pandemic Influenza A (H1N1) Virus. Vaccine Journal, 2011, 18, 520-522.	3.2	19
168	The combination of valacyclovir with an anti-TNF alpha antibody increases survival rate compared to antiviral therapy alone in a murine model of herpes simplex virus encephalitis. Antiviral Research, 2013, 100, 649-653.	1.9	19
169	<i>In vitro</i> Susceptibility of Geographically and Temporally Distinct Zika Viruses to Favipiravir and Ribavirin. Antiviral Therapy, 2017, 22, 613-618.	0.6	19
170	Randomized Controlled Ferret Study to Assess the Direct Impact of 2008–09 Trivalent Inactivated Influenza Vaccine on A(H1N1)pdm09 Disease Risk. PLoS ONE, 2014, 9, e86555.	1,1	19
171	The quest for a nanoparticle-based vaccine inducing broad protection to influenza viruses. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 2563-2574.	1.7	18
172	<i>In Vitro</i> Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance. Antimicrobial Agents and Chemotherapy, 2022, 66, .	1.4	18
173	Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity. Antiviral Therapy, 2010, 15, 579-586.	0.6	17
174	Drug Susceptibility and Replicative Capacity of Multidrug-Resistant Recombinant Human Cytomegalovirus Harboring Mutations in <i>UL56</i> and <i>UL54</i> Genes. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	17
175	Herpes simplex encephalitis in adult patients with MASP-2 deficiency. PLoS Pathogens, 2019, 15, e1008168.	2.1	17
176	Inhibition of the 3CL Protease and SARS-CoV-2 Replication by Dalcetrapib. ACS Omega, 2021, 6, 16584-16591.	1.6	17
177	Microglia are involved in phagocytosis and extracellular digestion during Zika virus encephalitis in young adult immunodeficient mice. Journal of Neuroinflammation, 2021, 18, 178.	3.1	17
178	Contrasting effects on ganciclovir susceptibility and replicative capacity of two mutations at codon 466 of the human cytomegalovirus UL97 gene. Journal of Clinical Virology, 2010, 49, 296-298.	1.6	16
179	Reduced airborne transmission of oseltamivir-resistant pandemic A/H1N1 virus in ferrets. Antiviral Therapy, $2011, 16, 775-779$ .	0.6	16
180	Therapeutic Activity of Intramuscular Peramivir in Mice Infected with a Recombinant Influenza A/WSN/33 (H1N1) Virus Containing the H275Y Neuraminidase Mutation. Antimicrobial Agents and Chemotherapy, 2012, 56, 4375-4380.	1.4	16

#	Article	IF	CITATIONS
181	Both IRF3 and especially IRF7 play a key role to orchestrate an effective cerebral inflammatory response in a mouse model of herpes simplex virus encephalitis. Journal of NeuroVirology, 2018, 24, 761-768.	1.0	16
182	In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses. Viruses, 2020, 12, 1139.	1.5	16
183	Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice. Antiviral Research, 2020, 179, 104807.	1.9	16
184	Neurovirulence and latency of drugâ€resistant clinical herpes simplex viruses in animal models. Journal of Medical Virology, 2010, 82, 1000-1006.	2.5	15
185	Evaluation of Recombinant 2009 Pandemic Influenza A (H1N1) Viruses Harboring Zanamivir Resistance Mutations in Mice and Ferrets. Antimicrobial Agents and Chemotherapy, 2013, 57, 1784-1789.	1.4	15
186	Epitope mapping of the 2009 pandemic and the A/Brisbane/59/2007 seasonal (H1N1) influenza virus haemagglutinins using mAbs and escape mutants. Journal of General Virology, 2014, 95, 2377-2389.	1.3	15
187	Activity of the Oral Neuraminidase Inhibitor A-322278 against the Oseltamivir-Resistant H274Y (A/H1N1) Influenza Virus Mutant in Mice. Antimicrobial Agents and Chemotherapy, 2009, 53, 791-793.	1.4	14
188	Permissive changes in the neuraminidase play a dominant role in improving the viral fitness of oseltamivir-resistant seasonal influenza A(H1N1) strains. Antiviral Research, 2015, 114, 57-61.	1.9	14
189	The E119D neuraminidase mutation identified in a multidrug-resistant influenza A(H1N1)pdm09 isolate severely alters viral fitness inÂvitro and in animal models. Antiviral Research, 2016, 132, 6-12.	1.9	14
190	Proteaseâ€activated receptor 1 inhibition protects mice against thrombinâ€dependent respiratory syncytial virus and human metapneumovirus infections. British Journal of Pharmacology, 2018, 175, 388-403.	2.7	14
191	Oseltamivir–zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses. Antiviral Research, 2014, 105, 54-58.	1.9	13
192	Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines. Vaccine, 2014, 32, 5730-5739.	1.7	13
193	Contrasting Effects of W781V and W780V Mutations in Helix N of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Antiviral Drug Susceptibility. Journal of Virology, 2015, 89, 4636-4644.	1.5	13
194	Synergistic PA and HA mutations confer mouse adaptation of a contemporary A/H3N2 influenza virus. Scientific Reports, 2019, 9, 16616.	1.6	13
195	Human metapneumovirus activates NOD-like receptor protein 3 inflammasome via its small hydrophobic protein which plays a detrimental role during infection in mice. PLoS Pathogens, 2019, 15, e1007689.	2.1	13
196	Mutations in the fusion protein heptad repeat domains of human metapneumovirus impact on the formation of syncytia. Journal of General Virology, 2017, 98, 1174-1180.	1.3	13
197	Long-term impairment of Streptococcus pneumoniae lung clearance is observed after initial infection with influenza A virus but not human metapneumovirus in mice. Journal of General Virology, 2011, 92, 1662-1665.	1.3	12
198	Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis. Journal of Infectious Diseases, 2019, 220, 1302-1306.	1.9	12

#	Article	IF	Citations
199	Evaluation of pre- and post-fusion Human metapneumovirus F proteins as subunit vaccine candidates in mice. Vaccine, 2020, 38, 2122-2127.	1.7	12
200	Protective role of CX3CR1 signalling in resident cells of the central nervous system during experimental herpes simplex virus encephalitis. Journal of General Virology, 2017, 98, 447-460.	1.3	12
201	Parenteral Peramivir Treatment for Oseltamivir-Resistant 2009 Pandemic Influenza A H1N1 Viruses. Journal of Infectious Diseases, 2011, 204, 1641-1642.	1.9	11
202	Analysis of HHV-6 mutations in solid organ transplant recipients at the onset of cytomegalovirus disease and following treatment with intravenous ganciclovir or oral valganciclovir. Journal of Clinical Virology, 2013, 58, 279-282.	1.6	11
203	Evaluation of Epstein-Barr Virus, Human Herpesvirus 6 (HHV-6), and HHV-8 Antiviral Drug Susceptibilities by Use of Real-Time-PCR-Based Assays. Journal of Clinical Microbiology, 2013, 51, 1244-1246.	1.8	11
204	Effect of In Vitro Syncytium Formation on the Severity of Human Metapneumovirus Disease in a Murine Model. PLoS ONE, 2015, 10, e0120283.	1,1	11
205	Adjuvant effect of the human metapneumovirus (HMPV) matrix protein in HMPV subunit vaccines. Journal of General Virology, 2015, 96, 767-774.	1.3	11
206	The I427T neuraminidase (NA) substitution, located outside the NA active site of an influenza A(H1N1)pdm09 variant with reduced susceptibility to NA inhibitors, alters NA properties and impairs viral fitness. Antiviral Research, 2017, 137, 6-13.	1.9	11
207	Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid Immunization. Journal of Infectious Diseases, 2019, 219, 365-374.	1.9	11
208	The REinfection in COVIDâ€19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers. Influenza and Other Respiratory Viruses, 2022, 16, 916-925.	1.5	11
209	Strain-Dependent Impact of G and SH Deletions Provide New Insights for Live-Attenuated HMPV Vaccine Development. Vaccines, 2019, 7, 164.	2.1	10
210	Novel calixarene-based surfactant enables low dose split inactivated vaccine protection against influenza infection. Vaccine, 2020, 38, 278-287.	1.7	10
211	Antiviral Drugs Against Herpesviruses. Advances in Experimental Medicine and Biology, 2021, 1322, 1-30.	0.8	10
212	Infectivity of healthcare workers diagnosed with coronavirus disease 2019 (COVID-19) approximately 2 weeks after onset of symptoms: A cross-sectional study. Infection Control and Hospital Epidemiology, 2022, 43, 102-104.	1.0	10
213	Emergence of an Oseltamivir-Resistant Influenza A/H3N2 Virus in an Elderly Patient Receiving a Suboptimal Dose of Antiviral Prophylaxis. Journal of Clinical Microbiology, 2013, 51, 4234-4236.	1.8	9
214	Cytomegalovirus quantification in plasma with Abbott RealTime CMV and Roche Cobas Amplicor CMV assays. Journal of Virological Methods, 2015, 225, 1-3.	1.0	9
215	The combination of oseltamivir with azithromycin does not show additional benefits over oseltamivir monotherapy in mice infected with influenza A(H1N1)pdm2009 virus. Journal of Medical Virology, 2017, 89, 2239-2243.	2.5	9
216	In vitro and in vivo evidence of a potential A(H1N1)pdm09 antigenic drift mediated by escape mutations in the haemagglutinin Sa antigenic site. Journal of General Virology, 2017, 98, 1224-1231.	1.3	9

#	Article	IF	Citations
217	Single-cell transcriptomics of the ventral posterolateral nucleus-enriched thalamic regions from HSV-1-infected mice reveal a novel microglia/microglia-like transcriptional response. Journal of Neuroinflammation, 2022, 19, 81.	3.1	9
218	In Vitro Properties and Virulence of Contemporary Recombinant Influenza B Viruses Harboring Mutations of Cross-Resistance to Neuraminidase Inhibitors. Viruses, 2019, 11, 6.	1.5	8
219	Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet. Antimicrobial Agents and Chemotherapy, 2021, 65, e0039021.	1.4	8
220	Predominant role of IPS-1 over TRIF adaptor proteins in early innate immune response against Zika virus in mice. Journal of General Virology, 2018, 99, 209-218.	1.3	8
221	Both Cerebral and Hematopoietic Deficiencies in CCR2 Result in Uncontrolled Herpes Simplex Virus Infection of the Central Nervous System in Mice. PLoS ONE, 2016, 11, e0168034.	1.1	8
222	Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada. Emerging Infectious Diseases, 2019, 25, 838-840.	2.0	7
223	Genetics of symptom remission in outpatients with COVID-19. Scientific Reports, 2021, 11, 10847.	1.6	7
224	Seroconversion to Seasonal Influenza Viruses after A(H1N1)pdm09 Virus Infection, Quebec, Canada. Emerging Infectious Diseases, 2012, 18, 1132-4.	2.0	6
225	Impact of R152K and R368K neuraminidase catalytic substitutions on in vitro properties and virulence of recombinant A(H1N1)pdm09 viruses. Antiviral Research, 2018, 154, 110-115.	1.9	6
226	Engineering of Live Chimeric Vaccines against Human Metapneumovirus. Pathogens, 2020, 9, 135.	1.2	6
227	Human Respiratory Syncytial Virus-Induced Immune Signature of Infection Revealed by Transcriptome Analysis of Clinical Pediatric Nasopharyngeal Swab Samples. Journal of Infectious Diseases, 2021, 223, 1052-1061.	1.9	6
228	Droplet Digital PCR and Immunohistochemistry Techniques to Detect Zika Virus in the Central Nervous System of Mice. Methods in Molecular Biology, 2020, 2142, 41-57.	0.4	6
229	Molecular Pathway of Influenza Pan-neuraminidase Inhibitor Resistance in an Immunocompromised Patient. Antiviral Therapy, 2019, 24, 581-587.	0.6	6
230	Avian Cell Line DuckCelt®-T17 Is an Efficient Production System for Live-Attenuated Human Metapneumovirus Vaccine Candidate Metavac®. Vaccines, 2021, 9, 1190.	2.1	6
231	Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay. Vaccine, 2022, 40, 2635-2646.	1.7	6
232	Diagnosis of Viral Infections. , 0, , 291-319.		5
233	A Cluster of Three Cases of <i>Hantavirus </i> Pulmonary Syndrome among Canadian Military Personnel. Canadian Journal of Infectious Diseases and Medical Microbiology, 2016, 2016, 1-4.	0.7	5
234	Impact of a large deletion in the neuraminidase protein identified in a laninamivirâ€selected influenza A/Brisbane/10/2007 (H3N2) variant on viral fitness ⟨i⟩inÂvitro⟨ i⟩ and in ferrets. Influenza and Other Respiratory Viruses, 2016, 10, 122-126.	1.5	5

#	Article	IF	CITATIONS
235	Peramivir susceptibilities of recombinant influenza A and B variants selected with various neuraminidase inhibitors. Antiviral Therapy, 2017, 22, 711-716.	0.6	5
236	Design and Validation with Influenza A Virus of an Aerosol Transmission Chamber for Ferrets. International Journal of Environmental Research and Public Health, 2019, 16, 609.	1.2	5
237	The recruitment of peripheral blood leukocytes to the brain is delayed in susceptible BALB/c compared to resistant C57BL/6 mice during herpes simplex virus encephalitis. Journal of NeuroVirology, 2019, 25, 372-383.	1.0	4
238	Effects of Different Drug Combinations in Immunodeficient Mice Infected with an Influenza A/H3N2 Virus. Microorganisms, 2020, 8, 1968.	1.6	4
239	Hypersusceptibility of Human Cytomegalovirus to Foscarnet Induced by Mutations in Helices K and P of the Viral DNA Polymerase. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	4
240	Fitness of influenza A and B viruses with reduced susceptibility to baloxavir: A miniâ€review. Reviews in Medical Virology, 2021, 31, e2175.	3.9	4
241	DNA polymerases of herpesviruses and their inhibitors. The Enzymes, 2021, 50, 79-132.	0.7	4
242	Droplet digital PCR to investigate quasiâ€species at codons 119 and 275 of the A(H1N1)pdm09 neuraminidase during zanamivir and oseltamivir therapies. Journal of Medical Virology, 2017, 89, 737-741.	2.5	3
243	Comparison of early and recent influenza A(H1N1)pdm09 isolates harboring or not the H275Y neuraminidase mutation, in vitro and in animal models. Antiviral Research, 2018, 159, 26-34.	1.9	3
244	Molecular and epidemiologic investigation of a rhinovirus outbreak in a neonatal intensive care unit. Infection Control and Hospital Epidemiology, 2019, 40, 245-247.	1.0	3
245	Differential impact of various substitutions at codon 715 in region II of HSV-1 and HCMV DNA polymerases. Antiviral Research, 2021, 188, 105046.	1.9	3
246	A novel bioluminescent herpes simplex virus 1 for in vivo monitoring of herpes simplex encephalitis. Scientific Reports, 2021, 11, 18688.	1.6	3
247	Evaluation of anticoagulant agents for the treatment of human metapneumovirus infection in mice. Journal of General Virology, 2018, 99, 1367-1380.	1.3	3
248	Replication and transmission of an influenza A(H3N2) virus harboring the polymerase acidic I38T substitution, in guinea pigs Journal of General Virology, 2021, $102$ , .	1.3	3
249	Heterosubtypic Protection Conferred by the Human Monoclonal Antibody PN-SIA28 against Influenza A Virus Lethal Infections in Mice. Antimicrobial Agents and Chemotherapy, 2015, 59, 2647-2653.	1.4	2
250	The Val430lle neuraminidase (NA) substitution, identified in influenza B virus isolates, impacts the catalytic 116Arg residue causing reduced susceptibility to NA inhibitors. Antiviral Research, 2019, 170, 104561.	1.9	2
251	Antiviral Drug Resistance in Herpesviruses. , 2017, , 87-122.		2
252	Herpesvirus Resistance to Antiviral Drugs. , 2017, , 1185-1211.		2

#	Article	IF	Citations
253	Predictive risk factors for hospitalization and response to colchicine in patients with COVID-19. International Journal of Infectious Diseases, 2022, 116, 387-390.	1.5	2
254	In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes. Antiviral Research, 2022, 202, 105328.	1.9	2
255	Duration of isolation and contagiousness in COVID-19 patients receiving tocilizumab and dexamethasone: a case series. Infection Control and Hospital Epidemiology, 2022, , 1-14.	1.0	1
256	Reply to "Calibration Technologies for Correct Determination of Epstein-Barr Virus, Human Herpesvirus 6 (HHV-6), and HHV-8 Antiviral Drug Susceptibilities by Use of Real-Time-PCR-Based Assaysâ€∙ Journal of Clinical Microbiology, 2013, 51, 2014-2014.	1.8	0
257	Antiviral Drug Resistance in Herpesviruses. , 2014, , 1-32.		0
258	Resistance of Herpesviruses to Antiviral Agents. , 2018, , 233-267.		0
259	Novel antiviral compounds and combination therapy for influenza viruses. Virologie, 2019, 23, 32-35.	0.1	0
260	Zika virus and impact on male fertility. , 2021, , 289-298.		0
261	HUMAN PARAINFLUENZA 2 RELATED ILLNESS AND A DEATH IN A GROUP OF CAPTIVE WESTERN LOWLAND GORILLAS (GORILLA GORILLA). Journal of Zoo and Wildlife Medicine, 2019, 50, 713.	0.3	0